Market Data
Market Cap₹1,460.42 Cr.
52W High₹759
Current Price₹505.15
52W Low₹476.85
Down from 52W High33.4 %
Face Value₹1
Performance
ROCE65.49 %
ROE49.63 %
EPS (TTM)₹1.51
EPS Prev Qtr₹5.6
EPS Last Year₹4.83
EBITDA Qtr₹4.33 Cr.
Book Value₹38
Financial Health
Debt/Equity0.02
Debt/Profit0.05
Total Assets₹140.438 Cr.
Dividend Yield0.76 %
Promoter Holding46.52 %
Earning Power47.55 %
Valuation
Stock P/E27.06
Industry P/E33.81
Price to Book13.43
Price to Sales2.86
Graham Number₹125.7
Key Metrics
Dividend/Share
₹1
Face Value
₹1
About Amrutanjan Health Care Ltd
Healthcare · Pharmaceuticals
Amrutanjan Health Care Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹1,460.42 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a high ROCE of 65.49%, indicating efficient use of capital.
- ROE is strong at 49.63%, reflecting profitability relative to shareholder equity.
- The company maintains a low debt-to-equity ratio of 0.02, suggesting minimal financial risk.
- Promoter holding stands at 46.52%, indicating significant management control and alignment of interests.
Weaknesses
- The P/E ratio of 26.75 may reflect that the stock is overvalued relative to earnings.
- The P/B ratio of 13.28 suggests the market values the company at a premium to its book value.
- The dividend yield is low at 0.77%, which may not attract income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 117.7 | 141.04 | 149.77 | 102.97 |
| ↳ QoQ Growth | - | +19.8% | +6.2% | -31.2% |
| Expenses | 102.73 | 117.49 | 125.83 | 98.64 |
| Operating Profit | 14.97 | 23.54 | 23.94 | 4.33 |
| OPM % | 12.72% | 16.69% | 15.98% | 4.21% |
| Other Income | 4.3 | 4.12 | 4.73 | 3.81 |
| Interest | 0.05 | 0.05 | 0.05 | 0.04 |
| Depreciation | 1.56 | 1.62 | 1.61 | 1.92 |
| EBITDA | 16.53 | 25.16 | 25.55 | 6.25 |
| EBITDA Margin % | 14.04% | 17.84% | 17.06% | 6.07% |
| Profit Before Tax | 19.21 | 26.36 | 21.02 | 6.07 |
| Tax % | 27.33% | 26.21% | 22.93% | 28.01% |
| Net Profit | 13.96 | 19.45 | 16.19 | 4.37 |
| ↳ QoQ Growth | - | +39.3% | -16.8% | -73.0% |
| EPS | 4.83 | 6.73 | 5.6 | 1.51 |
Balance Sheet
| Mar 2016 | |
|---|---|
| Equity Capital | 2.923063 |
| Reserves | 105.81794 |
| Borrowings | 2.5 |
| Other Liabilities | 29.2 |
| Total Liabilities | 140.43839 |
| Fixed Assets | 28.914658 |
| CWIP | 0.7160464 |
| Investments | 8.99 |
| Other Assets | 101.82 |
| Total Assets | 140.43839 |
Cash Flows
| Mar 2016 | |
|---|---|
| Cash from Operating Activity | 20.698833 |
| Cash from Investing Activity | 4.1613603 |
| Cash from Financing Activity | -13.104199 |
| Net Cash Flow | 11.755994 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 46.52% | 46.52% | 46.52% | 46.52% |
| FIIs % | 2.38% | 2.27% | 2.17% | 2.44% |
| DIIs % | 12.9% | 13% | 12.66% | 12.28% |
| Public % | 32.18% | 32.09% | 32.2% | 32.06% |
| No. of Shareholders | 47,954 | 46,675 | 45,805 | 45,135 |
Major Shareholders (>1%)
- Goodhealth Holdings Private LimitedPromoter and Promoter Group20.15%
- Sambhuprasad SivalenkaPromoter and Promoter Group10.34%
- Dsp Small Cap FundPublic Shareholding3.80%
- Sambhu Prasad SivalenkaPromoter and Promoter Group3.60%
As of 2026-06-30View all shareholders →